Kazia Therapeutics (Kazia Therapeutics) Price-to-Tangible-Book

: (As of Today)

View and export this data going back to 1999. Start your Free Trial

As of today (2024-04-23), Kazia Therapeutics's share price is $0.39. Kazia Therapeutics's Tangible Book per Share of Jun. 2023 for the quarter that ended in Jun. 2023 was $-0.15. Hence, Kazia Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Kazia Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Kazia Therapeutics's highest Price to Tangible Book Ratio was 33.46. The lowest was 1.37. And the median was 4.10.

KZIA's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.67
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Kazia Therapeutics's share price is $0.39. Kazia Therapeutics's Book Value per Sharefor the quarter that ended in Jun. 2023 was $0.36. Hence, Kazia Therapeutics's P/B Ratio of today is 1.10.

Kazia Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Kazia Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Price-to-Tangible-Book

Get a 7-Day Free Trial

33.46

27.12

10.10

Kazia Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Price-to-Tangible-Book	Get a 7-Day Free Trial															10.10	34.79	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Kazia Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kazia Therapeutics Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's Price-to-Tangible-Book falls into.

Kazia Therapeutics Price-to-Tangible-Book Calculation

Kazia Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2023 )
	=	0.39	/	-0.154
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Kazia Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204